Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tozinameran + famtozinameran (Pfizer)
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Pfizer Bivalent vaccine, commercially known as Comirnaty Bivalent, is an mRNA-based vaccine developed by Pfizer and BioNTech to prevent COVID-19. This formulation is bivalent, meaning it contains two messenger RNA (mRNA) components: one (tozinameran) encoding the spike protein of the original (ancestral) SARS-CoV-2 strain, and another (famtozinameran) encoding the spike protein of the Omicron BA.4 and BA.5 variants. The vaccine utilizes lipid nanoparticle (LNP) technology to deliver the mRNA into host cells, where it is translated into spike proteins that trigger a robust adaptive immune response, including the production of neutralizing antibodies and activation of T-cells. It was primarily authorized and used as a booster dose to enhance protection against emerging variants of concern.
- Brand names
- Comirnaty Original/Omicron BA.4-5Comirnaty Bivalent
- Other names
- Pfizer-BioNTech COVID-19 Vaccine, BivalentPfizer Bivalent vaccinetozinameran/famtozinameran
02
Targets
80S ribosome (Ribosome and ribosomal components)ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on tozinameran + famtozinameran (Pfizer).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tozinameran + famtozinameran (Pfizer).